{
    "clinical_study": {
        "@rank": "82501", 
        "arm_group": {
            "arm_group_label": "vaccine + chemokine modulatory regimen", 
            "arm_group_type": "Experimental", 
            "description": "Cycle 1, approximately 4 weeks (up to 12 weeks) after surgery, will include the DC vaccine and oral celecoxib only. Cycle 2, approximately week 4, will include the DC vaccine, celecoxib, and the CKM regimen. Week 5 will be a week of rest and discontinuation of oral celecoxib. Weeks 6-18, if directed by their local oncologists, standard of care chemotherapy. Week 19 is a week of rest. Cycle 3, week 20, will include the DC vaccine, celecoxib, and the CKM regimen. Cycle 4, week 24, will include the DC vaccine, celecoxib, and the CKM regimen.\nCKM regimen includes an additional 200 mg dose of celecoxib, intravenous rintatolimod, and intravenous interferon alfa-2b. The CKM regimen is given on days Tuesday through Friday of Cycles 2-4."
        }, 
        "brief_summary": {
            "textblock": "This trial is to determine the safest dose of a triple combination (chemokine modulatory\n      regimen or CKM) of celecoxib, interferon alfa (IFN), and rintatolimod that can be given with\n      a DC vaccine as treatment of peritoneal surface malignancies after standard of care surgery.\n\n      The first phase of this study will determine the safest dose of IFN that can be given in\n      combination with celecoxib and rintatolimod along with a DC vaccine. The doses of celecoxib\n      (400 mg) and rintatolimod (200 mg) will be consistent while the dose of IFN will be\n      increased (5, 10, or 20 MU/m2) as participants are enrolled to the trial. The high dose of\n      IFN in combination with celecoxib and rintatolimod will be used for the next phase of the\n      clinical trial. After surgery, participants will receive 2 cycles of the investigational\n      treatment.\n\n      The second phase of this study will test if the investigational treatment has any effects on\n      peritoneal surface malignancies. The doses of the combination determined in the first phase\n      will be used in this phase of the clinical trial. After surgery, participants will receive 2\n      cycles of the investigational treatment, followed by standard chemotherapy as determined by\n      their oncologist, and then 2 more cycles of the investigational treatment."
        }, 
        "brief_title": "\u03b1DC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface", 
            "Malignant Peritoneal Mesothelioma", 
            "Peritoneal Carcinomatosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Mesothelioma", 
                "Pancreatic Neoplasms", 
                "Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This trial will evaluate the safety and effectiveness of autologous alpha-type-1 polarized\n      dendritic cell (alpha-DC1) vaccines (patients' autologous alpha-DC1s loaded with autologous\n      tumor material), combined with a systemic chemokine modulation regimen [CKM; intravenous\n      rintatolimod (TLR3 ligand, a derivative of Poly-I:C) + intravenous interferon-alfa + oral\n      celecoxib] as adjuvant therapy, after cytoreductive surgery (CRS) and hyperthermic\n      intraperitoneal chemotherapy (HIPEC), in patients with peritoneal surface malignancies\n      (PSM), including malignant peritoneal mesothelioma and peritoneal carcinomatosis (PC) of\n      appendiceal and colorectal origin.\n\n      All patients judged to have peritoneal surface malignancy and considered able to be\n      cytoreduced to Peritoneal Cancer Index (PCI) Completeness of Cytoreduction (CC) score of 1\n      or less will undergo CRS + HIPEC. Postoperative immunotherapy will start 4 weeks, but no\n      later than 12 weeks based on patient recovery, after CRS + HIPEC.\n\n      Immunotherapy regimen will include four cycles of intranodal (3M cells) and intradermal (3M\n      cells) \u03b1DC1 vaccines. Each booster \u03b1DC1 vaccine dose (treatment cycles 2-4) will be followed\n      by 4-days of systemic CKM, starting the day after vaccination (IFN\u03b1 [dose-escalation: 5-20\n      MU/m2], intravenous [IV], once a day for 4 days; rintatolimod [short-half-life TLR3 ligand]\n      200 mg intravenous [IV], on Wednesday and Friday only of the CKM regimen; and celecoxib 200\n      mg, orally, twice a day for 4 days). In order to avoid overlap between experimental\n      immunotherapy and potential adjuvant chemotherapy (which can be clinically indicated as a\n      part of standard care in the subset of patients), the experimental treatments will be\n      interrupted after cycles 1 and 2, to allow adjuvant chemotherapy that is done for each\n      patient's clinical care, and is not a part of this research study (see the schema below).\n      Whenever clinically indicated as a part of standard care, adjuvant chemotherapy may start at\n      least 5 days after completion of the 2nd cycle of immunotherapy (first booster vaccine plus\n      the first CKM). The 3rd cycle of immunotherapy may start at least 5 days after the\n      completion of chemotherapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically confirmed peritoneal surface malignancies, including\n             malignant peritoneal mesothelioma and peritoneal carcinomatosis (PC) from presumed\n             appendiceal and colorectal primary tumors. Most patients will have received extensive\n             prior treatments, due to the recurrent nature of PC. Prior therapies involve previous\n             CRS, local and systemic chemotherapy, and their different numbers. None of these\n             prior treatments disqualifies the patient from receiving the protocol-mandated\n             experimental treatment.\n\n          -  Patients must be deemed able to undergo optimal cytoreductive surgery (CRS) defined\n             as CC-score of 0 or 1 based on imaging.\n\n        Cytoreduction is defined as the burden of residual disease nodules left at the end of\n        surgery (CC-0: no visible disease; CC-1: residual tumor nodules \u2264 2.5 mm in size; CC-2:\n        residual tumor nodules 2.5 mm - 2.5 cm in size; CC-3: residual tumor nodules > 2.5 cm in\n        size).\n\n          -  Patients may be enrolled in the study regardless of prior chemotherapy regimens\n\n          -  An ECOG performance status of 0, 1 or 2\n\n          -  Age equal to 18 years or older\n\n          -  Patients must be able to understand and be willing to sign a written informed consent\n             document\n\n          -  Able to swallow pills\n\n          -  Must have normal organ and marrow function as defined below:\n\n        Platelet \u2265 75,000/\u00b5L Hemoglobin \u2265 9.0 g/dL Hematocrit \u2265 27.0% Absolute Neutrophil Count\n        (ANC) \u2265 1500/\u00b5L WBC >2000/mm3 Creatinine < 1.5 x institutional upper limit of normal\n        (ULN), OR Creatinine clearance \u2265 50 mL/min/1.73 m2 for patients with creatinine levels\n        greater than 1.5 x ULN Total bilirubin \u2264 1.5 x ULN AST(SGOT) and ALT(SGPT) \u2264 2.5 X ULN\n\n        Exclusion Criteria:\n\n          -  Patients currently treated with systemic immunosuppressive agents, including\n             steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment\n\n          -  Patients with active autoimmune disease or history of transplantation. Patients with\n             indolent or chronic autoimmune disease not requiring steroid treatment are considered\n             eligible.\n\n          -  Patients who are pregnant or nursing\n\n          -  Patients experiencing a cardiac events (acute coronary syndrome, myocardial\n             infarction, or ischemia) within the 3 months prior to accrual\n\n          -  Patients with a New York Heart Association classification of III or IV\n\n          -  Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or NSAIDs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "168", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151448", 
            "org_study_id": "12-110", 
            "secondary_id": [
                "5P01CA132714-05", 
                "12-110"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "vaccine + chemokine modulatory regimen", 
                "description": "Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)", 
                "intervention_name": "DC vaccine", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Alpha-type-1 polarized dendritic cells", 
                    "alpha DC1", 
                    "\u03b1DC1"
                ]
            }, 
            {
                "arm_group_label": "vaccine + chemokine modulatory regimen", 
                "description": "Administered at 200 mg, once a day orally, starting the day of discharge from surgery through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the off treatment visit at approximately week 28. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.", 
                "intervention_name": "Celecoxib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Celebrex", 
                    "Celebra", 
                    "Onsenal"
                ]
            }, 
            {
                "arm_group_label": "vaccine + chemokine modulatory regimen", 
                "description": "Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.", 
                "intervention_name": "Interferon Alfa-2b", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Interferon-\u03b12b", 
                    "Intron A", 
                    "IFN-\u03b12b", 
                    "IFN\u03b1", 
                    "IFN", 
                    "NSC #377523"
                ]
            }, 
            {
                "arm_group_label": "vaccine + chemokine modulatory regimen", 
                "description": "Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.", 
                "intervention_name": "rintatolimod", 
                "intervention_type": "Biological", 
                "other_name": [
                    "PolyIC12U", 
                    "Ampligen\u00ae", 
                    "poly I: polyC12U", 
                    "Polyinosinic:polycytidylic-polyuridylic acid", 
                    "polyriboinosinic/polyribocytidylic (uridylic) acid"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferon Alfa-2b", 
                "Interferons", 
                "Ampligen", 
                "Reaferon", 
                "Celecoxib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase 1/2 Trial Evaluating \u03b1DC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies", 
        "overall_contact": {
            "email": "bartlettdl@upmc.edu", 
            "last_name": "David L Bartlett, MD", 
            "phone": "(412) 692-2852"
        }, 
        "overall_contact_backup": {
            "email": "gtribble@upmc.edu", 
            "last_name": "Gail Tribble, RN, BSN, OCN, CCRC", 
            "phone": "412-647-8205"
        }, 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "David L Bartlett, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Our primary objective is to test whether our combined immunotherapy regimen (\u03b1DC1 vaccines + CKM) is safe and whether it can prolong time-to-progression (TTP) in patients with peritoneal surface malignancies after optimal CRS + HIPEC with standard of care chemotherapy.", 
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "measure": "Time to disease progression", 
                "safety_issue": "No", 
                "time_frame": "9 to 18 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151448"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pittsburgh", 
            "investigator_full_name": "Pawel Kalinski", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "estimate overall survival (OS)", 
                "measure": "How long participants live after surgery", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "TTP will be correlated with the development of positive DTH reaction to autologous tumor cell lysates, and may also be correlated with the changes in the blood samples and available DTH biopsies of the treated subjects.", 
                "measure": "Changes in the immune system", 
                "safety_issue": "No", 
                "time_frame": "Approximately at weeks 0, 1, 4, 20, 24, and 28"
            }
        ], 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Pawel Kalinski", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}